SCHEMBL24252351

SCHEMBL24252351

Nc1cnnc2cc(-c3cc(B(O)O)ccc3OCC(F)(F)F)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 5/20 0.41
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
PDE10A Q9Y233 3/20 0.37
AAK1 Q2M2I8 9/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
G6PD P11413 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SCN5A Q14524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25266455 0.95 SCN9A (0.38) SCN9AALOX5APFEN1PDE10AAAK1
Formic Acid SCHEMBL30467675 0.95 SCN9A (0.38) SCN9AALOX5APFEN1PDE10AAAK1
SCHEMBL26771306 0.92 SCN9A (0.42) SCN9AALOX5APFEN1PDE10AAAK1
SCHEMBL25212150 0.88 SCN9A (0.37) SCN9AALOX5APFEN1PDE10AAAK1
SCHEMBL24252271 0.85 PDE10A (0.33) PDE10ADHFR
SCHEMBL24252763 0.84 PDE10A (0.35) PDE10ADHFR
SCHEMBL26773859 0.84 KDR (0.39) PDE10ADHFR
SCHEMBL24252639 0.84 PDE10A (0.33) ALOX5APFEN1PDE10A
SCHEMBL24252357 0.83 PDE10A (0.36) ALOX5APFEN1PDE10ADHFR
SCHEMBL24252384 0.83 PDE10A (0.32) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SCN9A 3732/4885ALOX5AP 246/4885FEN1 2638/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SCN9A 3732/4885ALOX5AP 246/4885FEN1 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.